NovoCure Limited (NVCR) has a MoatMap StockRank of 58/100 based on Quality (40/100), Value (34/100), and Momentum (69/100) factor scores. The current signal is HOLD. NovoCure develops Tumor Treating Fields (TTFields) for cancer therapy. While innovative, the business model is currently unprofitable, highly volatile, and dependent on clinical trial binary outcomes, failing our quality and margin of safety criteria.
NovoCure Limited is a global oncology company focused on developing and commercializing its proprietary Tumor Treating Fields (TTFields) technology for various solid tumor cancers. TTFields are electric fields that disrupt cancer cell division, representing a novel, non-invasive therapeutic modality. The company's competitive advantage lies in its unique technology, which has regulatory approvals for glioblastoma and mesothelioma, positioning it as an innovator in cancer treatment with a growing intellectual property portfolio.
| Price | $17.24 |
| Market Cap | $2.0B |
| P/E (Forward) | -15.36 |
| Price/Book | 6.30 |
| Return on Equity | -50.0% |
| Return on Invested Capital | -20.5% |
| Debt/Equity | 71.04 |
| Gross Margin | 75.4% |
| Operating Margin | -38.7% |
| Revenue Growth | 12.3% |
| Free Cash Flow | $5M |
NovoCure Limited operates in the Medical Devices industry, part of the Healthcare sector (Switzerland).